About
Small Molecules
Areas of Focus
Categories
Small Molecule PharmaceuticalChina
Clinical Trials (22)
View allTotal Trials
22
As Lead Sponsor
16
As Collaborator
6
Total Enrollment
5,072
By Phase
PHASE4: 3PHASE2: 7PHASE1/PHASE2: 3PHASE3: 4PHASE1: 1
By Status
COMPLETED: 10UNKNOWN: 6RECRUITING: 4NOT_YET_RECRUITING: 1TERMINATED: 1
Clinical Trials Pipeline21 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
Today
Hover over trial bars to see details
Recent Trials
NCT07076680Lead Sponsor
A Real-World Study of Elacestrant in Patients With HR+/HER2- Advanced Breast Cancer and ESR1 Mutations
N/ARecruiting
100 participants
Started: Aug 1, 2025 · Completed: Jul 1, 2027
NCT06548919Lead Sponsor
Current Status of Treatment for Chinese Patients With ESR1-mutated HR+/HER2-advanced Breast Cancer
N/ARecruiting
450 participants
Started: Aug 8, 2024 · Completed: Dec 31, 2027
NCT06544577Lead Sponsor
Safety of Elacestrant in ER+/HER2- and ESR1 Mutations MBC
N/ARecruiting
350 participants
Started: Jul 13, 2024 · Completed: Aug 1, 2026
NCT06047535Lead Sponsor
Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) Combined With Isotretinoin for Maintenance Treatment of Patients With High-Risk Neuroblastoma in First Complete Response.
PHASE4Not yet recruiting
62 participants
Started: Oct 31, 2023 · Completed: Aug 15, 2027
NCT05790447Collaborator
Thymalfasin-based PRaG Mode for Advanced Refractory Solid Tumors
PHASE2Recruiting
60 participants
Started: Apr 1, 2023 · Completed: Dec 31, 2025
Locations (1)
Headquarters
Shanghai, China
Map
Loading map...